US 12,233,090 B2
Bispecific or-gate chimeric antigen receptor responsive to CD20 and CD19
Yvonne Y. Chen, Los Angeles, CA (US); Eugenia Zah, Los Angeles, CA (US); and Michael C. Jensen, Seattle, WA (US)
Assigned to The Regents of the University of California, Oakland, CA (US); and Seattle Children's Hospital, Seattle, WA (US)
Filed by The Regents of the University of California, Oakland, CA (US); and Seattle Children's Hospital, Seattle, WA (US)
Filed on Apr. 1, 2024, as Appl. No. 18/623,246.
Application 18/623,246 is a continuation of application No. 18/238,210, filed on Aug. 25, 2023, granted, now 12,053,491.
Application 18/238,210 is a continuation of application No. 17/569,107, filed on Jan. 5, 2022.
Application 17/569,107 is a continuation of application No. 15/535,972, granted, now 11,253,546, issued on Feb. 22, 2022, previously published as PCT/US2015/065620, filed on Dec. 14, 2015.
Claims priority of provisional application 62/091,854, filed on Dec. 15, 2014.
Prior Publication US 2024/0261334 A1, Aug. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); C12N 5/0783 (2010.01); A61K 38/00 (2006.01)
CPC A61K 35/17 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); A61K 39/464424 (2023.05); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70596 (2013.01); C07K 16/2803 (2013.01); C07K 16/2887 (2013.01); C07K 16/46 (2013.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2239/29 (2023.05); A61K 2239/48 (2023.05); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/40 (2013.01); C12N 2510/00 (2013.01)] 18 Claims
 
1. A polypeptide comprising a CD20-OR-CD19 chimeric antigen receptor (CAR), wherein the CAR comprises from N- to C-terminus:
a) an anti-CD20 scFv comprising a variable heavy domain and a variable light domain from SEQ ID NO: 3;
b) a (EAAAK (SEQ ID NO: 1)) n linker, wherein n is 1, 2, 3, 4, 5, or 6;
c) an anti-CD19 scFv comprising a variable light domain and a variable heavy domain from SEQ ID NO: 4;
d) a spacer domain;
e) a transmembrane domain;
f) a co-stimulatory domain of SEQ ID NO: 8; and
g) a CD3-zeta cytoplasmic signalling domain of SEQ ID NO: 9.